← Back to patent-cliff list
Deuterated psilocybin analog
Tier C — Watch / tradeDeuterated psilocybin analog
Cybin Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT2A, 5-HT1A
Indications (approved)：Major depressive disorder, Depression, Depressive disorder, Anxiety
Regional status
US
Phase III
2024-12-17
EU
Phase III
2025-07-18
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Deuterated psilocybin analog?
Approved indications include: Major depressive disorder, Depression, Depressive disorder, Anxiety.
When does the Deuterated psilocybin analog patent expire?
No public expiry year is available for Deuterated psilocybin analog yet; this page updates once verified.
How do I get a quote for Deuterated psilocybin analog intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01